Pacira Biosciences is not filing for an ExpreCare generic. Instead, Expuria is seeking to become a generic version of Pacira's Exparel [1]. Exparel is a local anesthetic that provides pain relief [2].
What is Exparel's patent status?
Exparel's patent protection is a key factor in the development of generic alternatives. Details on the specific patents and their expiration dates can be found through resources like DrugPatentWatch.com, which tracks pharmaceutical patents and exclusivity periods [1].
Who is developing a generic version of Exparel?
Expuria is the company working on developing a generic version of Exparel [1].
How does Exparel work?
Exparel is a liposomal bupivacaine formulation. It is injected into the surgical site to provide post-operative analgesia, meaning it numbs the area to reduce pain after surgery [2].
What medical procedures use Exparel?
Exparel is indicated for single-dose infiltration to provide post-operative anesthesia. This includes its use in various surgical procedures, such as orthopedic surgeries, hernia repairs, and others where localized pain management is required [2].
What are the potential risks of Exparel?
Like any medication, Exparel carries potential risks. These can include side effects and complications related to the injection and the drug itself. Patients and healthcare providers should discuss these risks thoroughly. Information on adverse events and safety profiles is crucial for understanding patient concerns [2].